Blood Product Transfusion Procedure Note (Pediatric Oncology)

Date of Service: [Calendar date]

Procedure Start Time: [Local time HH:MM]

Location: [Inpatient unit / Outpatient infusion center / ED / OR/PACU / Other: specify]

Ordering Clinician: [Name, credentials]

Administering Clinician: [Name, credentials] (Include only if different from ordering clinician.)

[One-line procedure statement summarizing product, special processing, vascular access, and monitoring]

(If any regulatory or safety-critical element is missing—consent status, unit identifiers, start/stop times, baseline vitals—do not omit the field. Insert placeholder text noting the information is pending and who will obtain it.)

Clinical Indication

[Primary indication in clinical terms] [Clinical context: chemotherapy effect / HSCT/BMT support / procedure prophylaxis / other as applicable] [Measured lab value with date/time of most recent pre-transfusion labs, or state unavailability with clinical rationale for proceeding] [Transfusion threshold/trigger used and whether per service protocol or individualized] [Relevant clinical modifiers: fever/sepsis, active bleeding, hemodynamic status, prior transfusion reactions, alloimmunization history] [If symptom-based rather than threshold-based, state symptom rationale explicitly] (Compose as 3–6 sentences in narrative paragraph format.)

Consent

• Status: [On file dated [date] / Obtained today / Emergent exception / Declined] (If emergent or declined, document rationale and policy pathway used.)
• Consenting party: [Patient (age-appropriate) / Parent / Legal guardian] [Interpreter: not needed / used—language and interpreter ID]
• Scope: [Single episode / Admission-long / Time-limited ongoing for chronic transfusion, expires [date]]
• Discussion: [Confirmed discussion of product type, expected benefits, material risks, alternatives, and opportunity for questions]

Product Details & Special Processing

• Product Type: [PRBC / Platelets apheresis / Platelets pooled / Plasma / Cryoprecipitate / Granulocytes]
• Quantity Planned: [Number of units and/or mL] ([mL/kg dose basis])
• Special Requirements: [Irradiated / Leukoreduced / CMV-seronegative / CMV-safe / Pathogen-reduced / Washed / Volume-reduced / HLA-matched / Antigen-negative / ABO/Rh strategy considerations / None beyond standard institutional practice] (List all that apply.)
• Planned Premedication: [Acetaminophen / Diphenhydramine / Steroid / Diuretic / None] [Dose and rationale if applicable]
• Rate Plan: [Standard / Slow start: initial rate and duration / Maximum rate: specify / Split unit / Other modification]

Pre-Transfusion Safety Verification

• Order verification: [Correct product, dose, route, and timeframe confirmed]
• Patient identification: [Two identifiers verified; bedside product-to-patient verification via two-person check / approved electronic method]
• Compatibility: [Type and screen / Crossmatch status] [Compatible unit issued] [Alloantibody history and antigen requirements if applicable]
• IV access: [PIV / Implanted port / Tunneled CVC / PICC] [Lumen: specify] [Patency confirmed]
• Filter/tubing: [Standard blood filter in use; tubing within policy time limits]
• Baseline assessment: [Baseline vitals obtained; focused clinical assessment completed] (If baseline vitals not obtained, document variance and corrective action.)

Premedication Administered

(Include this section only if premedication was given. If considered but not given, document rationale in Product Details section.)

• [Medication name] [Dose in mg or mg/kg] [Route] [Time] [Indication]
• [Additional medication if applicable]

Administration Details

(Repeat the following subsection for each unit or product transfused.)

Unit [#]: [Component Type]

• Component as transfused: [Type with attributes: irradiated, leukoreduced, CMV strategy, etc.]
• Unit Number: [Unique donation/unit identifier]
• ABO/Rh: [As displayed on product tag]
• Volume infused: [mL] ([mL/kg])
• Start Time: [HH:MM]
• Completion Time: [HH:MM]
• Rate: [Initial rate] [Slow-start details if applicable] [Subsequent rate changes with times]
• Monitoring: [Vital signs recorded at required intervals per policy—baseline, early check at approximately 15 minutes, completion; see transfusion flowsheet for values]
• Patient tolerance: [Tolerated without signs or symptoms of reaction / Symptoms observed—see Reaction Documentation]
• Line management: [Line flushed per policy; no medications added to blood product]

Reaction Surveillance

Monitored closely during first 15 minutes and throughout transfusion; patient and caregiver instructed to report chills, rash, dyspnea, chest or back pain, nausea, anxiety, or any change.

Reaction Documentation

(Include this subsection only if a suspected or confirmed reaction occurred: concerning symptoms, abnormal vitals, premature discontinuation, treatment given, or blood bank notification required.)

• Onset: [Time from start of unit to symptom onset] [Unit running at onset] [Volume infused at onset]
• Signs/symptoms: [Temperature change / Rash/urticaria / Respiratory symptoms / Blood pressure changes / Dyspnea/hypoxia / Chest or back pain / Hemoglobinuria / Nausea/vomiting / Anxiety / Other]
• Immediate actions with times: [Transfusion stopped] [IV maintained with NS or other solution] [Bedside clerical re-check performed] [Provider assessment at bedside] [Blood bank/transfusion service notified]
• Therapies administered: [Medication name, dose, route, time, and response for each]
• Diagnostic workup: [Post-transfusion samples: DAT, hemolysis labs, blood cultures as applicable] [Imaging if obtained] [Times sent]
• Disposition/outcome: [Symptoms resolved / ongoing] [ICU transfer if applicable] [Transfusion resumed: yes/no with authorization and rationale]
• Suspected classification: [Allergic / FNHTR / TACO / TRALI / Acute hemolytic / Septic / Other] (Label as "suspected" unless confirmed.)
• Reporting: [Institutional transfusion reaction report completed per policy]

Post-Transfusion Assessment & Plan

• Clinical response: [Tolerance and clinical status at end of transfusion; reference end-of-transfusion vitals in flowsheet]
• Complications: [None / Description and current status]
• Post-transfusion labs: [Post-Hgb with timing for RBCs / Post-platelet count with timing for platelets including increment assessment if evaluating refractoriness / No immediate labs planned with rationale]
• Ongoing plan: [Additional units anticipated / Re-transfusion thresholds / Changes to premedication strategy / Special product requirements going forward]
• Outpatient instructions: [Delayed reaction symptoms to watch for and contact information for urgent concerns] (Include for outpatient infusion only.)

Documentation Linkage

• [Transfusion flowsheet completed and referenced]
• [Blood administration record completed]
• [Blood bank product tag(s) scanned/attached]
• Variance: [None / Description of variance (missing vitals, delayed start, interrupted transfusion), patient impact, and corrective action]

Attestation: I performed or directly supervised the transfusion, verified the medical indication, and confirmed monitoring per institutional policy. Any deviations are documented above.

Electronic Signature: [Name, credentials, date/time]